West Pharmaceutical Services (NYSE:WST), a leading provider of injectable packaging and delivery systems, announced it has entered into a definitive agreement to sell all manufacturing and supply rights for its SmartDose 3.5mL On-Body Delivery System, along with associated facilities, to AbbVie (NYSE:ABBV) for $112.5 million in cash at closing, subject to customary working capital and other adjustments.
The transaction is expected to close in mid-2026, pending satisfaction of standard closing conditions.
Until closing, West will continue to fulfill commercial supply obligations and execute ongoing project commitments related to the SmartDose 3.5mL program, which may include milestone-based payments prior to the transfer.
The SmartDose 3.5mL platform, a wearable on-body injector designed for subcutaneous delivery of large-volume biologics, accounted for approximately 4% of West’s total fiscal 2025 revenue.
Following the divestiture, West will retain and continue to develop and manufacture its broader SmartDose portfolio, including the larger-volume SmartDose 10mL system, as part of its ongoing focus on high-growth drug delivery technologies.
Management indicated that additional details on the financial impact of the transaction and updated strategic priorities will be provided when the company issues its 2026 guidance during its fourth-quarter 2025 earnings call in February 2026.